Introduction
Coronary artery disease remains one of the leading causes of death in Ireland,1 the UK,2 and worldwide. Despite advances in management, it is a major source of morbidity and mortality in our healthcare system. Numerous trials (PROVE-IT,3 ISIS-1,4 ISIS-2,5 ISIS-3,6 ISIS-4,7 AIRE,8 CAPRICORN9) have established the prognostic benefits associated with adequate secondary prevention post ST-elevation myocardial infarction (STEMI).
National Institute for Health and Care Excellence (NICE) guidelines10 recommend all patients discharged post-STEMI should be offered treatment with an angiotensin-converting enzyme inhibitor (ACEi), beta bloc
